Literature DB >> 16472496

[Methicillin resistant Staphylococcus aureus infection postoperatory complications and prognosis of patients with lower extremity amputations].

M Lourdes del Río-Solá1, Enrique San Norberto-García, José A González-Fajardo, Santiago Carrera-Díaz, Vicente Gutiérrez-Alonso, Carlos Vaquero-Puerta.   

Abstract

BACKGROUND AND
OBJECTIVE: Methicillin-resistant Staphylococcus aureus (MRSA) is associated with an increasing morbimortality when compared with other microorganisms. The aim of this study was to examine the complications and prognosis of the presence of MRSA in vascular patients with amputation of lower limbs. PATIENTS AND
METHOD: We included patients who had lower extremity amputation in our department in 2004 and displayed positive surgical wounds cultures. We compared patients with MRSA positive cultures with other microrganisms. We evaluated general characteristics, operative indications, surgical wounds microbiology, reamputations, morbimortality and mean time of stay in hospital.
RESULTS: 117 patients (median age 73, 68% male) underwent lower extremity amputation. 82 of them had positive cultures and MRSA were isolated in 30% cases. Two two groups were comparable and no statistical differences were found in relation to reamputation rate, morbimortality and mean time of stay in hospital.
CONCLUSION: Presence of MRSA does not represent an additional risk of reamputation or an increase of postoperative complications. Careful wound surveillance, through wound debridement and optimal administration of antibiotics must be applied to all patients, regardless of the bacterial flora.

Entities:  

Mesh:

Year:  2006        PMID: 16472496     DOI: 10.1157/13084021

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  1 in total

1.  Hospital infection after major amputations.

Authors:  José Maria Pereira de Godoy; Janalice Vasconcelos Ribeiro; Lívia Andrioli Caracanhas; Maria de Fátima Guerreiro Godoy
Journal:  Ann Clin Microbiol Antimicrob       Date:  2010-05-19       Impact factor: 3.944

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.